Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RAGE Inhibition to Decrease Cancer Therapy Related Cardio Toxicity in Women With Early Breast Cancer

NCT05256745 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT05256745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05256745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RAGE Inhibition to Decrease Cancer Therapy Related Cardio Toxicity in Women With Early Breast Cancer
Lead sponsor
Georgetown University
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 6, 2023
Completion date
December 31, 2026
Enrollment
48 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer related cognitive decline, non-metastatic breast cancer